Exploring New Strategies for the Management of Nonalcoholic Steatohepatitis: NOT a Trivial Pursuit
medscape.org/viewarticle/998763
Nonalcoholic Steatohepatitis: Mission Possible!: Learn to recognize, diagnose, and manage nonalcoholic steatohepatitis (NASH) and metabolic ...
medscape.org/viewarticle/998939
Does Your Patient Have Steatotic Liver Disease? A Virtual Patient Challenge: Learn to better manage patients with risk factors for steatotic liver disease.
medscape.org/viewarticle/991961
Nonalcoholic Steatohepatitis: Mission Possible!: Learn to recognize, diagnose, and manage nonalcoholic steatohepatitis (NASH) and metabolic ...
medscape.org/viewarticle/998939
❓ Treatment decisions can be challenging for steatotic liver disease. How do you compare with the experts? ms.spr.ly/6189ib0uz
Does Your Patient Have Steatotic Liver Disease? A Virtual Patient Challenge: Learn to better manage patients with risk factors for steatotic liver disease.
medscape.org/viewarticle/991961
Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mln
reuters.com/markets/deals/italys-alfasigma-buy-drugmaker-intercept-nearly-800-mln-2023-09-26/
Hedge funds are betting against these stocks the most in this sell-off: These stocks made the cut for high short interest from the end of August through the ...
cnbc.com/2023/09/28/hedge-funds-are-betting-against-these-stocks-the-most-in-this-sell-off.html
Paid articlePaid
This Top Stock, With 159% Growth, Just Surged For A Second Day: Shares of CBAY stock surged for a second day Friday as analysts compared CymaBay liver-disease ...
investors.com/news/technology/cbay-stock-how-cymabay-with-huge-growth-this-year-is-taking-on-intercept-genfit/
FDA declines to approve Intercept's fatty liver disease drug: The U.S. Food and Drug Administration on Thursday declined to grant accelerated approval for ...
reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-intercepts-fatty-liver-disease-drug-2023-06-22/
US FDA panel votes against approval of Intercept fatty liver drug, cites safety issues
reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-votes-against-accelerated-approval-intercept-fatty-liver-drug-2023-05-19/
US FDA staff flag 'serious' safety risks for Intercept's fatty-liver disease treatment
reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-flag-liver-damage-concerns-about-intercepts-nash-treatment-2023-05-17/
Madrigal's NASH drug reports positive results, stock jumps: Madrigal Pharmaceuticals reported positive results for its treatment for NASH ...
businessinsider.com/madrigals-nash-drug-reports-positive-results-stock-jumps-2022-12
Paid articlePaid
Intercept Will Ask Yet Again for FDA to Approve Its NASH Drug: A newly identified condition thought to affect many adults in Western countries ...
barrons.com/articles/intercept-nash-drug-fda-stock-51657293097
Paid articlePaid
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics